Format

Send to

Choose Destination
Nat Rev Endocrinol. 2018 Oct;14(10):605-623. doi: 10.1038/s41574-018-0087-0.

Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway.

Author information

1
Center for Bone Quality, Leiden University Medical Center, Leiden, Netherlands.
2
Center for Bone Quality, Leiden University Medical Center, Leiden, Netherlands. s.e.papapoulos@lumc.nl.

Abstract

The WNT signalling pathway is a key regulator of bone metabolism, particularly bone formation, which has helped to define the role of osteocytes - the most abundant bone cells - as orchestrators of bone remodelling. Several molecules involved in the control of the WNT signalling pathway have been identified as potential targets for the development of bone-building therapeutics for patients with osteoporosis. Several of these molecules have been investigated in animal models, but only inhibitors of sclerostin (which is produced by osteocytes) have been investigated in phase III clinical studies. Here, we review the rationale for these developments and the specificity and potential off-target actions of WNT-based therapeutics. We also describe the available preclinical and clinical studies and discuss the benefits and risks of using sclerostin inhibitors for the management of patients with osteoporosis.

PMID:
30181608
DOI:
10.1038/s41574-018-0087-0

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center